Pacira Biosciences Inc (PCRX) valuation
Pacira Biosciences P/E ratio history
Pacira Biosciences trades at 101.1 times its earnings over the last twelve months and 11.5 times the earnings analysts expect over the next twelve. At its last 5 fiscal year ends its P/E ranged from 18.2 (year to Dec 2020) to 161.8 (year to Dec 2025), with a median of 65.4.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $25.88 | $0.16 | 161.8 | 7.9 |
| Dec 31, 2024 | $18.84 | -$2.15 | n/m | 6.4 |
| Dec 31, 2023 | $33.74 | $0.89 | 37.9 | 8.1 |
| Dec 31, 2022 | $38.61 | $0.34 | 113.6 | 10.5 |
| Dec 31, 2021 | $60.17 | $0.92 | 65.4 | — |
| Dec 31, 2020 | $59.84 | $3.28 | 18.2 | — |
| Dec 31, 2019 | $45.30 | -$0.28 | n/m | — |
| Dec 31, 2018 | $43.02 | -$0.02 | n/m | — |
| Dec 31, 2017 | $45.65 | -$1.08 | n/m | — |
| Dec 31, 2016 | $32.30 | -$1.02 | n/m | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Pacira Biosciences valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Pacira BiosciencesPCRX | $1.43B | 101.1 | 11.5 | 1.9 |
| Eton PharmaceutcialsETON | $1.43B | 133.8 | 26.4 | 13.5 |
| Pennant GroupPNTG | $1.45B | 45.8 | 27.9 | 1.3 |
| Agilon HealthAGL | $1.42B | — | 77.3 | 0.2 |
| AnaptysbioANAB | $1.41B | — | 10.8 | 5.9 |
| Nutex HealthNUTX | $1.38B | 7.7 | 7.3 | 1.6 |
| Mineralys TherapeuticsMLYS | $1.50B | — | — | — |
| Alignment HealthcareALHC | $1.51B | 36.4 | 13.8 | 0.3 |
| Ocular TherapeutixOCUL | $1.53B | — | — | 29.3 |
| Peer median | 41.1 | 20.1 | 1.6 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: PCRX financials · PCRX returns
No forecast, no recommendation. This page describes Pacira Biosciences Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.